Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function.

被引：0
|
作者：
Weber, Donna
Wang, Michael
Chen, Christine
Belch, Andrew
Stadtmauer, Edward A.
Niesvisky, Ruben
Yu, Zhinuan
Olesnyckyj, Marta
Zeldis, Jerome
Knight, Robert D.
Dimopoulos, Meletios
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX USA
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Penn, Philadelphia, PA 19104 USA
[5] Cornell Univ, Presbyterian Hosp, New York, NY USA
[6] Celgene Corp, Summit, NJ USA
[7] Univ Athens, Sch Med, Dept Therapeut, Kifisia, Greece
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3547
引用
收藏
页码：1012A / 1013A
页数：2
相关论文
共 50 条
  • [41] THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Palumbo, A.
    Corradini, P.
    Cavo, M.
    Delforge, M.
    Weisel, K.
    Ocio, E.
    Di Raimondo, F.
    Oriol, A.
    Simcock, M.
    Miller, N.
    Slaughter, A.
    Peluso, T.
    Sternas, L.
    Zaki, M.
    Moreau, P.
    HAEMATOLOGICA, 2015, 100 : 83 - 83
  • [42] Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide plus Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Weisel, Katja
    Ocio, Enrique M.
    Cavo, Michele
    Corradini, Paolo
    Delforge, Michel
    Oriol, Albert
    Goldschmidt, Hartmut
    Jesus Blanchard, Maria
    Doyen, Chantal
    Morgan, Gareth J.
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Peluso, Teresa
    Sternas, Lars
    Zaki, Mohamed H.
    Moreau, Philippe
    BLOOD, 2014, 124 (21)
  • [43] Patient Outcomes By Prior Therapies and Depth of Response: Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
    San Miguel, Jesus F.
    Weisel, Katja
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Martinez-Lopez, Joaquin
    Chen, Christine I.
    Renner, Christoph
    Bahlis, Nizar J.
    Yu, Xin
    Teasdale, Terri
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    BLOOD, 2013, 122 (21)
  • [44] Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study
    Bahlis, Nizar
    Samaras, Christy
    Reece, Donna
    Sebag, Michael
    Matous, Jeffrey
    Berdeja, Jesus
    Shustik, Jesse
    Schiller, Gary
    Ganguly, Siddhartha
    Song, Kevin
    Seet, Christopher
    Acosta-Rivera, Mirelis
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Liu, Hongjuan
    Gentili, Christian
    Siegel, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S162
  • [45] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Jian Hou
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Dao-bin Zhou
    Li Yu
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Honeylet Wortman-Vayn
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Journal of Hematology & Oncology, 6
  • [46] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Hou, Jian
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [47] A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
    Richardson, Paul G.
    Jagannath, Sundar
    Moreau, Philippe
    Jakubowiak, Andrzej
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    White, Darrell J.
    Reece, Donna
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Deng, Wei
    Kroog, Glenn
    Singhal, Anil K.
    Lonial, Sagar
    BLOOD, 2012, 120 (21)
  • [48] Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial
    van de Donk, Niels W. C. J.
    Raab, Marc S.
    Besemer, Britta
    Siegel, David S.
    Anwer, Faiz
    Lipe, Brea
    White, Darrell
    Khan, Abdullah
    Pianko, Matthew J.
    Cheng, Yiming
    Chen, Lu
    Lin, Hongxia
    Maciag, Paulo
    Emerson, Joshua
    Amin, Alpesh
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S191 - S192
  • [49] Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Weisel, Katja
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Lopez, Joaquin Martinez
    Chen, Christine I.
    Spencer, Andrew
    Knop, Stefan
    Bahlis, Nizar J.
    Renner, Christoph
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
  • [50] Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Weisel, Katja
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Spencer, Andrew
    Knop, Stefan
    Renner, Christoph
    Bahlis, Nizar J.
    Amatya, Ramesh
    Yu, Xin
    Monzini, Mara Silvia
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian J.
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
12345